Federico Pulido

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment.

VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment.

Journal: Open forum infectious diseases

Published: June 05, 2026

Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain.

Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain.

Journal: The Lancet regional health. Europe

Published: May 10, 2026

Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL).

Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL).

Journal: The Journal of antimicrobial chemotherapy

Published: March 04, 2026

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 19, 2025

Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA Study.

Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA Study.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: July 17, 2025

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.

Journal: HIV medicine

Published: June 23, 2025

Impact of antiretroviral regimens containing integrase inhibitors on achieving viral suppression at ultra-low levels compared to other antiretroviral therapy strategies.

Impact of antiretroviral regimens containing integrase inhibitors on achieving viral suppression at ultra-low levels compared to other antiretroviral therapy strategies.

Journal: AIDS (London, England)

Published: June 11, 2025

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 12, 2024

Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men.

Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: October 08, 2024

Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians.

Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians.

Journal: The lancet. HIV

Published: February 23, 2024

Deep Sequencing on Proviral DNA: More Questions than Answers.

Deep Sequencing on Proviral DNA: More Questions than Answers.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: May 31, 2023

Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".

Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".

Journal: EBioMedicine

Published: February 22, 2023

Showing 1-12 of 98

Last Updated: 09/26/2026